Volume 12, No 5-6, Dec 2002

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 12 Issue 5-6, December 2002: 363-372

ORIGINAL ARTICLES

The associated regulators and signal pathway in rIL-16/CD4 mediated growth regulation in Jurkat cells

Xiao Ming ZHANG, Yong Hua XU*

Correspondence: Yong Hua XU(yhxu@sunm.shcnc.ac.cn )

IL-16 is a ligand and chemotactic factor for CD4⁺ T cells. IL-16 inhibits the CD3 mediated lymphocyte activation and proliferation. The effects of IL-16 on the target cells are dependent on the cell type, the presence of co-activators etc. To understand the regulation function and mechanism of IL-16 on target cells, we used a 130 a.a. recombinant IL-16 to study its effects on the growth of Jurkat T leukemia cells in vitro. We found that the rIL-16 stimulated the proliferation of Jurkat cells at low dose (10^-9M), but inhibited the growth of the cells at higher concentration (10^-5M). Results showed that 10^-5 M of rIL-16 treatment induced an enhanced apoptosis in Jurkat cells. The treatment blocked the expression of FasL, but up-regulated the c-myc and Bid expression in the cells. Pre-treatment of PKC inhibitor or MEK1 inhibitor markedly increased or decreased the rIL-16 induced growth-inhibiting effects on Jurkat cells, respectively. The results suggested that the rIL-16 might be a regulator for the growth or apoptosis of Jurkat cells at a dose-dependent manner. The growth-inhibiting effects of rIL-16 might be Fas/FasL independent, but, associated with the activation of PKC, up-regulated expression of c-Myc and Bid, and the participation of the ERK signal pathway in Jurkat cells.

FULL TEXT | PDF

Browse 2011